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Journal Club Article

Optimizing Vitamin D Status
to Reduce Colorectal Cancer Risk:
An Evidentiary Review
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Guiyun Zhou, MSN, CRNP, AOCNS®, Jill Stoltzfus, PhD,
and Beth Ann Swan, PhD, CRNP, FAAN
Vitamin D deficiency is common in the general public and in patients with cancer. Optimizing vitamin D intake is increasingly recognized in cancer risk reduction, particularly in decreasing colorectal cancer risk. Therefore, summarizing the current evidence to promote best practices related to vitamin D intake and colorectal cancer risk reduction is important. The
objectives of this article are to examine the current evidence regarding the impact of vitamin D on colorectal cancer risk
reduction and provide practice recommendations for clinicians. Relevant research articles from 2002–2008 were retrieved
from multiple electronic databases. Reference lists of relevant articles also were searched manually. Twenty-five research
reports were selected for this article: 4 randomized, controlled trials; 11 cohort or case-control studies measuring serum
25-OH-D levels; and 10 cohort studies reporting vitamin D intake. This review generated three themes: raising 25-OH-D
levels to a vitamin D sufficient state (32–100 ng/ml) achieved colorectal cancer risk reduction, increasing the intake of
vitamin D reduced colorectal cancer risk, and increasing vitamin D intake to 1,000 IU daily is safe and likely sufficient to
raise serum 25-OH-D levels above 32 ng/ml to achieve colorectal cancer risk reduction. Several practice recommendations
are suggested.

C

ancer is one of the most dreaded diagnoses from a
physiological, psychological, social, and spiritual
standpoint. According to the American Cancer Society ([ACS], 2008), cancer is the second leading
cause of death in the Untied States; about 1.5 million Americans were diagnosed with some form of cancer in
2008 and more than 500,000 died. In addition, the estimated
overall cost of cancer care reached $219 billion in 2007 (ACS).
Therefore, cancer prevention and risk reduction clearly are in
the national interest. Healthcare providers in particular have a
major responsibility in leading the fight against cancer by actively screening for cancer, treating cancer-predisposing conditions in a timely manner, and educating the public about cancer
prevention (including directly modifiable risk factors). Vitamin
D deficiency is considered one such risk factor for many types
of solid organ cancers, such as colorectal cancer, breast cancer,
and ovarian cancer (Garland et al., 2006).
Vitamin D deficiency is an epidemic health problem in the
industrial world; an estimated 1 billion people have vitamin D
deficiency (Cherniack, Levis, & Troen, 2008; Holick, 2007). In the
United States, 25%–58% of adolescents and adults are deficient in
vitamin D (Looker, Dawson-Hughes, Calvo, Gunter, & Sahyoun,
2002). Among patients with cancer, the prevalence of vitamin

At a Glance
 Vitamin D deficiency or insufficiency (less than 32 ng/ml or 80
nmol/L) is common in the general population and in patients
with cancer.

 Current evidence suggests that optimizing serum 25-OH-D
levels to the normal range of 32–100 ng/ml is associated
with colorectal cancer risk reduction.

 Daily vitamin D intake of 1,000 IU is safe and likely sufficient
to reduce colorectal cancer risk.
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D deficiency is much higher, approaching 90% (Everett, 2008;
Hershman et al., 2006; Li et al., 2007; Maddipatla et al., 2007).
Since the late 1990s, studying vitamin D’s effect on cancer has
been of increasing interest. Ecological studies have shown that
heightened sun exposure decreases internal solid organ cancers
(Boscoe & Schymura, 2006; Grant, 2007; Tuohimaa et al., 2007).
Researchers also have observed that higher intake of vitamin
D from diet, supplements, or both is associated with a lower
risk of colorectal and breast cancers (Garland et al., 2006; Lin
et al., 2007; Robien, Cutler, & Lazovich, 2007). A meta-analysis
of 18 randomized, controlled trials (RCTs) demonstrated that
vitamin D supplementation is associated with decreased total
mortality rates from life-threatening conditions such as cancer,
cardiovascular disease, and diabetes mellitus (Autier & Gandini,
2007). Many studies have similarly demonstrated an inverse
relationship between serum 25-OH-D levels and the risk of
colorectal, breast, and prostate cancers (Garland et al., 2006).
In addition, lower serum 25-OH-D levels are associated with
higher overall mortality, colorectal cancer–specific mortality,
and more advance-staged disease in breast cancer and colorectal
cancer (Fakih & Sunga, 2006; Goodwin, Ennis, Pritchard, Koo,
& Hood, 2008; Melamed, Michos, Post, & Astor, 2008; Ng et al.,
2008; Palmieri, MacGregor, Girgis, & Vigushin, 2006; Sieg, Sieg,
Dreyhaup, & Schmidt-Gayk, 2006).
The major research breakthrough demonstrating the direct
cancer risk reduction by vitamin D intake was reported by
Lappe, Travers-Gustafson, Davies, Recker, and Heaney (2007).
Their RCT studied 1,179 postmenopausal women and found
that taking 1,100 IU of vitamin D plus 1,400–1,500 mg of daily
calcium for four years resulted in a 60%–77% overall cancer risk
reduction. Following this report, the Canadian Cancer Society
(2007) updated their vitamin D recommendation to 1,000 IU
daily for typical adults during fall and winter months and yearround for adults at high risk for vitamin D deficiency. Subsequently, the Family Physicians Inquiries Network in the United
States published a pivotal report in response to this research
finding, suggesting that double-dose vitamin D lowers cancer risk
in women older than age 55 (Schumann & Ewigman, 2007).
It has been shown that vitamin D increases the apoptosis in
the colorectal epithelium, thereby reducing the risk of developing colorectal neoplasia (Holt et al., 2002, 2006). Indeed, many
cell types, including colorectal epithelial cells, contain vitamin
D receptors (VDRs) and express 1-a-hydroxylase. These cells
are, therefore, able to convert the circulating 25-OH-D into
active 1-25-OH-D metabolite, which, in turn, binds to the cells’
own VDRs to produce an autocrine effect by inducing cell differentiation and inhibiting proliferation, invasiveness, angiogenesis, and metastatic potentials (Giovannucci, 2006). Among a
large number of published research articles on the relationship
between vitamin D and various cancers, vitamin D’s effects on
colorectal cancer risk reduction has been most widely studied
and reported. Therefore, this evidentiary article will primarily
focus on the vitamin D effect in colorectal cancer risk reduction
with the goals of transforming scientific knowledge into clinical
practice. The objectives are to examine the effect of vitamin D
on colorectal cancer prevention and risk reduction and provide
practical recommendations for clinicians to evaluate and treat
vitamin D deficiency in patients, as well as optimize vitamin D
status accordingly.
E4

Definition of Terms
Vitamin D status, the prohormonal vitamin D representing the amount
of vitamin D storage in the body, is measured by the serum 25-OH-D
assay. Serum 25-OH-D levels less than 32 ng/ml (80 nmol/L) represent
hypo-vitamin D, or vitamin D deficiency or insufficiency (Holick, 2007).
25-OH-D (25-hydroxyvitamin D): 25-hydroxyvitamin D, known as
25-hydroxycholecalciferol, is the main vitamin D metabolite circulating
in plasma, consisting of 25-OH-D2 or 25-OH-D3, depending on its origin.
25-OH-D represents the vitamin D storage status in the human body
(Quest Diagnostics, 2008).
1-25-OH-D (1-25-hydroxyvitamin D): In the kidney, 25-OH-D changes into an active hormonal form of vitamin D called 1-25-OH-D. The active form helps control blood levels of calcium and phosphate balance.
1-25-OH-D level is highly controlled and regulated by the parathyroid
hormone (MedlinePlus Medical Encyclopedia, 2007a).
Confidence interval (CI): a range of values within which the population parameter is estimated to fall based on the statistic and the standard error (Munro, 2005)
Hazard ratio (HR): a measure of how often a particular event happens
in one group compared to how often it happens in another group over
time. In cancer research, HR = 1 indicates that no difference exists in
survival between the two groups; HR more than or less than 1 indicates
that survival is better in one of the groups (National Cancer Institute,
2008).
Interquartile range (IQR): the range of values extending from the
25th to the 75th percentile (Munro, 2005)
Odds ratio (OR): the probability of occurrence over the probability of
nonoccurrence (Munro, 2005)
Parathyroid hormone (PTH): is secreted by the parathyroid glands
to regulate the amount of calcium and phosphorous available in the
blood. The role of PTH includes raising the level of calcium in the blood,
decreasing the level of phosphorous in the blood, and increasing the
amount of active vitamin D available in the body (MedlinePlus Medical
Encyclopedia, 2007b).
Probability value (p value): in a statistical hypothesis test, the likelihood of getting the value of the statistic by chance alone (Munro, 2005)
Relative risk or risk ratio (RR): the risk given one condition versus
the risk given another condition (Munro, 2005)
R2 (variance): Squared multiple correlation is the amount of variance
accounted for the dependent variable by a combination of independent
variables (Munro, 2005).

Search Strategy
To retrieve the best evidence on vitamin D in colorectal
cancer prevention and risk reduction, electronic searches were
conducted in a variety of databases from 2002–2008 because,
generally speaking, evidence from the most recent five-year period is considered most relevant to research. An Ovid search was
carried out through Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, MEDLINE®, and
CINAHL® by using keywords vitamin D, 25 hydroxyvitamin D,
or cholecalciferol; colorectal neoplasm; clinical trial; cohort
studies; case-controlled studies; and epidemiologic studies.
The PubMed database was searched using vitamin D, colorectal
neoplasm, and clinical trial; vitamin D, colorectal neoplasm,
and cohort studies; vitamin D, colorectal neoplasm, and
case-controlled studies; and vitamin D, colorectal neoplasm,
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and epidemiologic studies. In addition, manual searches were
conducted on reference lists of relevant articles.
No systematic reviews or meta-analyses based on randomized
trials were found. Thirty-five potential research reports were
identified, including RCTs, cohort studies, case-control studies, and epidemiologic studies. The study interests regarding
vitamin D and colorectal neoplasm consist of vitamin D intake
from diet and supplements, sun exposure, serum 25-OH-D levels, vitamin D receptor polymorphism, and clinical trials with
vitamin D plus calcium intervention.
Twenty-five articles were selected for this evidentiary review
(see Table 1). The selection criteria were based on strengths of
evidence grade: RCTs with vitamin D as the intervention (n =
4); cohort or case-control studies using serum 25-OH-D level
measurement as the indicator variable reflecting vitamin D
status to assess association with colorectal neoplasm (including
colorectal adenomas and colorectal cancers) (n = 11); and cohort
or case-control studies measuring vitamin D intake from diet,
supplements, or both to examine the association with colorectal
neoplasm (n = 10). Studies on adenomas or colorectal polyps
also were selected because adenomas occur prior to cancer
development, making adenomas the true indicator of colorectal
cancer risk. Ecologic studies were not included, as these studies
provide only suggestive associations between regions or seasons
and sun exposure as the vitamin D proxy. Several studies based
on VDRs as the main vitamin D variables also were not included
because VDRs are not well understood and are probably less
practical from a clinical perspective.

Analysis and Synthesis
The Rating System for Levels of Evidence (Melnyk & FineoutOverholt, 2005) was used to grade the research studies selected
for this evidentiary review. There are seven levels of evidence in
this rating system, with level I representing evidence from a systematic review or meta-analysis through level VII representing
evidence from expert opinion and/or consensus groups (Melnyk
& Fineout-Overholt). Most studies in this review were rated as
level II (one well-designed RCT) or level IV (well-designed case
control and cohort studies). For discussion purposes, the studies
are grouped into three categories based on the major variable of
study interest: RCTs with vitamin D as an intervention, cohort
or case-control studies measuring 25-OH-D levels as the primary
variable, and cohort or case-control studies measuring vitamin
D intake from diet and supplements.

Vitamin D as a Research Intervention
in Randomized, Controlled Trials
Lappe et al. (2007) conducted a four-year, population-based,
placebo-controlled, three-arm RCT with 1,179 postmenopausal
women to examine the efficacy of calcium alone versus calcium
plus vitamin D on cancer incidence of all types. Results revealed
that the group taking 1,100 IU of vitamin D plus 1,400–1,500
mg of calcium daily had a 60% overall cancer risk reduction
compared to the placebo group (risk ratio [RR] = 0.4, 95% confidence interval [CI] 0.2–0.82, p = 0.01). Excluding cancer cases in the first year yielded an even more dramatic reduction in

risk of 77% (RR = 0.23, 95% CI 0.09–0.6, p < 0.005). Vitamin D
plus calcium treatment accounted 5.5% of the overall variance
(R 2 = 0.055), with the number needed to treat to prevent one
case of cancer equaling 20 patients. No difference existed
in toxicity profile among the three groups. The major limitations of this RCT are the short study duration of four years,
relatively few cases of cancer diagnosis (a total of 50 cancer
cases, 13 during the first year and 37 during the subsequent
three years), and the fact that cancer incidence was the secondary outcome.
In contrast, the double-blind, placebo-controlled Women’s
Health Initiative (WHI) study with 36,282 postmenopausal
women found that taking 1,000 mg of calcium plus 400 IU of
vitamin D daily for seven years revealed no protective effect
against colorectal cancer incidence as the secondary outcome
(RR = 1.08, 95% CI 0.86–1.34, p = 0.51) (Wactawski-Wende et
al., 2006). However, the nested study of 25-OH-D level measurement at baseline did show that higher 25-OH-D levels were associated with less colorectal cancer risk (odds ratio [OR] = 2.53
for the lowest quartile of less than 31 nmol/L compared with the
highest quartile of 58 nmol/L or higher, p = 0.02).
The WHI study has been subjected to several criticisms as
a result of vitamin D supplementation showing no protective
effects against colorectal cancer risk. First, the vitamin D dose
(400 IU per day) used in the study potentially was too low to
raise 25-OH-D levels into a meaningful range for a colorectal
cancer risk reduction because 400 IU per day did not correct
the vitamin D deficient status (Holick & Giovannucci, 2006).
Instead, it only raised the mean 25-OH-D level from baseline
42 nmol/L (16.8 ng/ml) to 47 nmol/L (18.8 ng/ml), whereas the
suggested 25-OH-D level needed to decrease colorectal cancer
risk is above 80 nmol/L (32 ng/ml) (Gorham et al., 2007).
Second, a poor adherence rate of less than 50% existed among
WHI study participants. Third, the concurrent use of overlapping estrogen therapy in the WHI study likely modified the
effects of the calcium plus vitamin D regimen (Ding, Mehta,
Fawzi, & Giovannucci, 2008). Ding et al. (2008) re-analyzed
the primary data from the WHI study to focus on women
concurrently taking supplemental estrogen. The hazard ratio
(HR) of colorectal cancer for women concurrently taking
calcium-vitamin D and estrogen was 1.5 (95% CI 0.96–2.33),
which suggested increased risk. The HR of colorectal cancer
for women taking calcium and vitamin D but concurrently assigned to the non-estrogen arm was 0.71 (95% CI 0.46–1.09),
which indicated a possible protective benefit. The interaction
between concurrent estrogen usage and calcium plus vitamin
D supplementation was statistically significant (p = 0.02).
Two small RCTs examined the effects of calcium plus vitamin
D on the epithelial cell proliferation from colorectal mucosa and
polyps (Holt et al., 2002, 2006). Findings demonstrated that 400
IU of vitamin D plus 1,500 mg of calcium daily for six months decreased epithelial cell proliferation of the colorectal mucosa and
colorectal polyp mucosa. Additionally, vitamin D plus calcium
appeared to inhibit polyp formation. The anti-carcinogenic effect of vitamin D was supported by an in vitro study, as human
colon cancer cells treated with vitamin D showed up-regulation
of VDR and 25-hydroxyvitamin D-1-a-hydroxylase expression
(Murillo, Matusiak, Benya, & Mehta, 2007). Previous casecontrol studies also have demonstrated that vitamin D increases
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Table 1. Studies Researching Vitamin D Deficiency
Study

Purpose

Design
and Method

Sample
and Setting

Major Findings

Level of
Evidence

Critique

Vitamin D as a Research Intervention in RCTs
Holt et al.,
2002

To examine the
relationship between serum levels of 25-OH-D,
1-25-OH-D, and
the indices of
colorectal epithelium proliferation
and differentiation

Three-arm RCT
consisting of
calcium (1,500
mg daily), calcium
(1,500 mg) plus
vitamin D (400
IU) daily, or 1-25OH-D 0.25 mcg
bid; duration was
six months.

139 outpatients with history of polyps
within three
years from two
hospitals in
New York City

The calcium plus vitamin D group
(adding baseline dietary vitamin D
equaling the total of 800 IU per day)
increased 25-OH-D levels by 44%
to 37 ng/ml. Epithelial cell proliferation decreased as serum 25-OH-D
increased, suggesting local autocrine
effects on circulating 25-OH-D. Calcium appeared to enhance the effects
of 25-OH-D.

II

The study provided the biologic explanation
for CRC control
from circulating
serum 25-OH-D.

Holt et al.,
2006

To study the effects of calcium
plus vitamin D
on colorectal
adenoma mucosa changes
measured by
biomarkers

Two-arm RCT
consisting of placebo or calcium
(1,500 mg) plus
vitamin D (400
IU) daily; duration
was six months.

19 outpatients
with small
polyps (less
than 9 mm)
from the population of one
New York City
hospital

Calcium plus vitamin D significantly
decreased the proliferative indices of
colorectal polyps, increased the VDR
staining, and strikingly decreased the
MUC5AC mucin staining (a proliferative marker).

II

The study
provided the
biological explanation for CRC
control effects
of calcium plus
vitamin D.

Lappe et al.,
2007

To determine
the efficacy of
placebo, calcium alone, and
calcium plus
vitamin D in
cancer incidence
as the secondary
outcome

Three-arm RCT
consisting of
placebo, calcium
(1,400–1,500
mg), or calcium
(1,400–1,500 mg)
plus vitamin D
(1,100 IU) daily;
duration was four
years.

1,179 community-dwelling
postmenopausal women

Calcium plus vitamin D significantly
increased 25-OH-D levels after 12
months of intervention (from 71.8
to 96 nmol/L); calcium plus vitamin D
decreased cancer incidence by 60%
(RR = 0.4, 95% CI 0.2–0.82, p =
0.01) over four years. If first year was
excluded, calcium plus vitamin D decreased cancer incidence by 77% (RR =
0.23, 95% CI 0.09–0.6, p < 0.005).

II

Cancer incidence
was not the
primary end
point. The fouryear duration
may not be long
enough because
of the latency
period for cancer
development.

WactawskiWende et
al., 2006

Whether calcium
(1,000 mg) plus
vitamin D (400
IU) daily helps
prevent CRC (the
second outcome)

Two-arm RCT
consisting of placebo or calcium
(500 mg) plus
vitamin D (200
IU) twice per day;
duration was
seven years.

36,282 nationwide postmenopausal
women from
the Women’s
Health Initiative study

Calcium plus vitamin D was effective
in reducing CRC risks (HR = 1.08,
95%CI 0.96–1.34, p = 0.51), but the
nested case-control analysis showed
that higher baseline 25-OH-D levels
had a trend of less CRC risk (OR =
2.53 for the lowest quartile of less
than 31 nmol/L compared with the
highest quartile of more than 58
nmol/L, p = 0.02).

II

Vitamin D at 400
IU per day may
be too small to
achieve a meaningful effect. The
treatment adherence rate was
low (less than
50%).

Dose Response Between Serum 25-OH-D Levels and CRC Risk
Feskanich et
al., 2004

To examine
the risk of colorectal cancer
in relation to
serum vitamin
D metabolites
(25-OH-D and
1-25-OH-D)

Case-control cohort study

193 cases from
the Nurses’
Health Study;
one CRC case
matched with
two health
controls

Serum 25-OH-D levels were inversely
associated with CRC risks, comparing
the top quartile of 35.3–44.5 ng/ml to
the bottom quintile of 14.9–17.4 ng/
ml (OR = 0.53, 95% CI, 0.27–1.04,
p = 0.02). No dose response existed
between 1-25-OH-D levels and CRC
risks.

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Freedman et
al., 2007

To examine the
relationship
between serum
25-OH-D levels
and cancer mortality

Cohort study
drawn from the
Third National
Health and Nutrition Examination
Survey

17,705 population-based
sample (older
than age 17)
in the United
States

Total cancer mortality was unrelated
to baseline 25-OH-D levels. Baseline
serum 25-OH-D levels of 80 nmol/L or
greater were associated with a 72%
risk reduction in CRC mortality (95%
CI 0.32–0.89), compared with levels
lower than 50 nmol/L (p = 0.02).

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

(Continued on next page)

CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort
studies.
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Table 1. Studies Researching Vitamin D Deficiency (Continued)
Study

Purpose

Design
and Method

Sample
and Setting

Major Findings

Level of
Evidence

Critique

Giovannucci
et al., 2006

To assess vitamin D status
with cancer
incidence and
cancer mortality

Cohort study
of male health
professionals in
the United States;
duration was 14
years.

47,800 men
with 4,286
diagnosed with
cancer; 2,025
died from
cancer.

An increment of predicated 25
nmol/L of 25-OH-D levels significantly decreased CRC risk by 37%
(RR = 0.63, 95% CI 0.48–0.83). For
digestive system cancers, an increment of 25 nmol/L of predicted 25OH-D level significantly reduced the
cancer incidence by 43% (RR = 0.57,
95% CI 0.46–0.71), with a 45%
reduction in cancer mortality
(RR = 0.55, 95% CI 0.41–0.74).

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Grau et al.,
2003

To assess the
independent
and joint effects
of calcium and
vitamin D status
on colorectal
advanced
adenoma recurrence

Cohort study
drawn from the
Calcium Polyps
Prevention Study

803 subjects
with two sets
of 25-OH-D
levels from a
multicenter
study in the
United States

Median 25-OH-D level was 29.1 ng/
ml. Higher 25-OH-D (more than 29.1
ng/ml) and calcium acted jointly to
decrease adenoma recurrence (RR =
0.71, 95% CI 0.57–0.89, p = 0.12).

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Jacobs et al.,
2006

To assess the
relationship
among serum
25-OH-D levels,
dietary intake
of vitamin D,
and colorectal
adenoma recurrence.

Cohort study
drawn from the
Ursodeoxycholicacid Multi-Clinic
Trial

211 adenoma
cases and 508
controls; outpatients were
from multiple
clinics in Arizona.

The association between 25-OH-D
levels and adenoma recurrence was
stronger for women with higher 25OH-D levels (33 ng/ml) (OR = 0.59,
95% CI 0.3–1.16) versus women
with low levels (17.2 ng/ml) than for
men (OR = 0.95, 95% CI 0.6–1.49).
An overall moderate, nonsignificant,
inverse association existed between
25-OH-D levels and adenoma.

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Miller et al.,
2005

To examine
whether calcium
and vitamin D
are associated
with increased
apoptosis in normal rectal biopsy
tissue

Cross-sectional
study

498 outpatients (174
adenoma
patients, 324
nonadenoma
patients) from
an East Coast
hospital

High calcium intake (more than 739
mg per day) increased the rectal apoptosis in patients with adenoma (OR =
3.4, 95% CI 0.9–12.9). Higher serum
25-OH-D levels (more than 34.9 ng/
ml) were strongly associated with the
rectal epithelium apoptosis scores in
patients free of adenoma (OR = 2.6,
95% CI 1.1–6.2), but slightly lower
in adenoma patients (p = 0.13) compared with lowest tertile (less than
20.9 ng/ml).

IV

The study
provided the
biological explanation for CRC
risk reduction.
The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Otani et al.,
2007

To investigate
the association
between serum
25-OH-D levels
and the risk of
CRC

Nested casecontrol study

38,373 population-based
sample from
Japan with 375
cancer cases
and 750 controls

Serum 25-OH-D level was not significantly associated with CRC risks in
men and women. A suggestive inverse
relationship existed in men. The lowest quintile of 25-OH-D (22.9 versus
32.1 ng/ml for men, 18.7 versus 27
ng/ml for women) was associated
with an elevated risk of rectal cancer
in men (OR = 4.6, 95% CI 1–2) and
women (OR = 2.7, 95% CI 0.94–7.6).

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

(Continued on next page)
CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort
studies.
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Table 1. Studies Researching Vitamin D Deficiency (Continued)
Study

Purpose

Design
and Method

Sample
and Setting

Major Findings

Level of
Evidence

Critique

Peters et al.,
2004

To study the
association of
vitamin D levels
with colorectal
adenoma risk
and the effects
of calcium and
HRT in relation
to vitamin D on
adenoma risk.

Nested casecontrol study
drawn from the
Prostate, Lung,
Colorectal, and
Ovarian Cancer
Screening Trial

772 cases and
777 controls
from a multicenter study

Women had a significantly decreased
risk for advanced adenoma (OR =
0.27, 95% CI 0.11–0.69; p = 0.0002),
comparing the highest quintile of 25OH-D levels (36.6–72.8 ng/ml) with
the lowest quintile (6.8–19.2 ng/ml).
No risk reduction was observed in
men. HRT increased 25-OH-D levels,
but no effect on adenoma risk reduction.

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Sieg et al.,
2006

To assess the
relationship
among serum
25-OH-D levels,
colorectal adenoma, and CRC
risk

Case-control
study

203 adenoma
cases, 98 CRC
cases, and 239
controls

Patients with CRC had significantly
lower 25-OH-D levels compared to
controls (winter was 15 ng/ml versus
23 ng/ml, p = 0.001; summer was 21
ng/ml versus 29 ng/ml, p = 0.0007).
Patients with adenoma had significantly lower 25-OH-D levels in winter
(24 ng/ml versus 29 ng/ml, p = 0.01).
25-OH-D levels showed an inverse
correlation to CRC stages.

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Wu et al.,
2007

To study the
association
between serum
25-OH-D levels
and the risk of
colorectal cancer

The National
Health Professional Study,
a nested casecontrol study, and
pooled analysis
from the Nurses’
Health Study

18,225 healthcare professionals in the
United States

Higher 25-OH-D levels significantly
reduced colon cancer risk, comparing
the highest (39.4 ng/ml) with the lowest quintile (18.4 ng/ml) (OR = 0.46,
95% CI 0.24–0.89, p = 0.005). Pooled
analysis showed decreased CRC and
colon cancer risks, compared the highest to lowest quintile (CRC was OR =
0.66, 95% CI 0.42–1.05, p = 0.01;
colon cancer was OR = 0.54, 95% CI
0.34–0.86, p = 0.002).

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

Vitamin D Intake and CRC Risk
Hartman et
al., 2005

To evaluate
the association
between calcium
and vitamin
D intake and
recurrence of
adenomatous
polyps

Cohort study
drawn from the
Polyps Prevention
Trial; duration
was four years.

2,079 participants from
a populationbased sample
in the United
States

Total vitamin D intake was inversely
associated (although weakly) with adenoma recurrence, fifth quintile (11.7
mcg per day) versus first quintile (3.35
mcg per day) (OR = 0.84, 95% CI
0.62–1.13, p = 0.03). Supplemental
calcium and vitamin D were inversely associated with adenoma recurrence (calcium user was OR = 0.82,
95% CI 0.68–0.99; vitamin D user
was OR = 0.82, 95% CI 0.68–0.99).
Vitamin D was slightly stronger in
preventing multiple polyp recurrences
(OR = 0.73, 95% CI 0.53–0.99).

IV

No 25-OH-D
level. The study
was not a RCT
design and
lacked causal
effect.

Kesse et al.,
2005

To study the
association between intake of
dietary calcium,
phosphorus and
vitamin D, dairy
products, and
the risk of adenomatous polyps
and CRC

Cohort study with
a duration of 6.9
years

74,524 population-based
French women
aged 40–65
years

The relative risk of adenoma and CRC
decreased with high calcium intake.
No association was found between
dietary vitamin D intake and risk of
colorectal tumors.

IV
Null finding

90% of subjects
had low D intake
of less than 400
IU per day. The
study was not a
RCT design and
lacked causal
effect.

(Continued on next page)

CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort
studies.
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Table 1. Studies Researching Vitamin D Deficiency (Continued)
Study

Purpose

Design
and Method

Sample
and Setting

Major Findings

Level of
Evidence

Critique

Lin et al.,
2005

To assess the
intake of calcium
and vitamin D in
relation to CRC
risk.

Cohort study

36,976 postmenopausal
women from
the Women’s
Health Initiative sample

Total calcium and vitamin D intake
(from diet and supplements) were
not associated with the risk of CRC.

IV
Null finding

Low median
vitamin D intake
of 271 IU per day
was unlikely to
be meaningful.
No 25-OH-D level. The study was
not a RCT design
and lacked
causal effect.

Martinez et
al., 2002

To assess whether calcium and
vitamin D intake
from diet and
supplements is
associated with
risk of adenoma
recurrence

Cohort study
drawn from the
Wheat Bran Fiber
Trial

1,304 men and
women with
polyps larger
than 3 mm
removed within
three months
in Arizona

Dietary calcium intake and total
calcium intake decreased adenoma
recurrence. Dietary vitamin D (174 IU
per day) was inversely (but weakly)
associated with adenoma recurrence.
No association was revealed for
supplemental sources of vitamin D
(400 IU per day) and total vitamin D
intake (455 IU).

IV

Dose cutoffs for
analysis are likely
too low to detect
differences. No
25-OH-D level.
The study was
not a RCT design and lacked
causal effect.

McCullough
et al., 2003

To examine the
association between intake of
calcium, vitamin
D, and dairy
products and the
risk of CRC

Cohort study
drawn from the
Cancer Prevention
Study II nutritional study; duration
was four years.

60,866 men
and 66,883
women from
a populationbased sample
in the United
States

Higher total calcium intake from diet
and supplements was associated with
a marginally lower risk for CRC (for
highest versus lowest quintiles, RR =
0.87, 95% CI 0.67–1.12, p = 0.02).
Supplemental calcium was more effective (RR = 0.69, 95% CI 0.49–0.96, 500
mg per day versus none). Total vitamin
D intake from diet and supplements
was inversely associated with CRC risk
(high quintile of more than 525 IU per
day versus low quintile of 110 IU per
day; RR = 0.8, 95% CI 0.62–1.02, p =
0.02), particularly in men (RR = 0.71,
95% CI 0.51–0.98, p = 0.02).

IV

For the effect of
vitamin D intake,
calcium intake,
and dairy product intake on
CRC risk, no 25OH-D level was
presented. The
study was not a
RCT design and
lacked causal
effect.

Mizoue et
al., 2008

To investigate
whether vitamin
D intakes are
associated with
CRC risk

Case-control
study

836 CRC cases
and 861 controls from two
university hospitals in Japan

High calcium decreased CRC risk.
Vitamin D intake (high quintile 488
IU per day for women, 532 IU per day
for men) was non-significantly inversely associated with CRC risk (p =
0.12). High calcium plus high vitamin
D plus high sun exposure had the
greatest inverse association with CRC
risk (RR = 0.38, 95% CI 0.21–0.68,
p = 0.001).

IV

For vitamin D
intake, calcium
intake and sun
exposure on CRC
risk, no 25-OH-D
level was presented. The study
was not a RCT
design and lacked
causal effect.

Oh et al.,
2007

To examine
calcium and
vitamin D intake
in relation to
distal colorectal
adenoma risk

Cohort study

48,115 women
from the
United States
taking part in
the Nurses’
Health Study

Total calcium intake was weakly
associated with reduced distal colorectal adenoma risk. Total vitamin
D intake was weakly associated with
reduced risk for distal colorectal adenomas (RR= 0.79, 95% CI 0.63–0.99;
p = 0.07), but more strongly with
distal colon adenoma risk (RR = 0.67,
95% CI 0.52–0.87, p = 0.004).

IV

For the affect of
vitamin D intake
and calcium intake on distal colorectal adenomas,
no 25-OH-D level
was presented.
The study was
not a RCT design
and lacked causal
effect.

(Continued on next page)
CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort
studies.
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Table 1. Studies Researching Vitamin D Deficiency (Continued)
Study

Purpose

Design
and Method

Sample
and Setting

Major Findings

Level of
Evidence

Critique

Park et al.,
2007

To examine the
associations
of calcium and
vitamin D intake
from foods and
supplements
with CRC risk

Cohort study

191,011 population-based
multiethnic
sample in the
western United
States

Total calcium intake significantly
reduced CRC risk in men and women.
Total vitamin D intake reduced CRC
risk in men only (RR = 0.72, 95% CI
0.51–1, p = 0.03). High dietary vitamin D reduced CRC risk for women
(RR = 0.78, 95% CI 0.63–0.96), particularly for those not taking supplements (RR = 0.69, 95% CI 0.52–0.93,
p = 0.03). Dairy products reduced
CRC risk, particularly for those not
taking supplements (for men, RR =
0.77, 95% CI 0.59–1.01; for women,
RR = 0.66, 95% CI 0.49–0.89).

IV

For vitamin D
intake, calcium
intake, and dairy
products’ affect
on CRC risk, no
25-OH-D level
was presented.
The study was
not a RCT design and lacked
causal effect.

Slattery et
al., 2004

To determine the
effect of intake
of calcium, vitamin D, and dairy
products on rectal cancer, and
the effect of the
BSM I (a type of
VDR) and poly-A
VDR polymorphisms on rectal
cancer risk

Case-control
study

2,306 rectal
cancer cases
and 2,749
controls from
a population
based in the
western United
States

Women’s rectal cancer risk was reduced with a high quintile of vitamin
D intake of more than 8.3 mcg per
day (OR = 0.52, 95% CI 0.32–0.85),
high intake of low-fat dairy products
(OR = 0.61, 95% CI 0.39–0.94), and
high calcium intake (OR = 0.39,
95% CI 0.24–0.64). High levels of
sunshine exposure for participants
younger than age 60 reduced rectal
cancer risk (OR = 0.62, 95% CI
0.42–0.93).

IV

For dietary calcium, vitamin D,
sunshine, and
dairy products’
affect on rectal
cancer risk, no
25-OH-D level
was presented.
The study was
not a RCT design and lacked
causal effect.

Theodoratou
et al., 2008

To evaluate the
associations
between CRC
risk and the
intake of vitamin
D and calcium;
to investigate
whether any
association is
mediated via the
VDR pathway

Case-control
study

A populationbased sample
in Scotland
with 2,070
CRC cases and
2,793 controls

Dietary vitamin D intake and total
vitamin D intake were significantly,
inversely associated with CRC risk,
with a 20%–23% reduction for high
(6–8.31 ug/d) versus low (2.51–2.76
mcg/d). Additional meta-analyses of
serum 25-OH-D from previous studies
showed an inverse association between 25-OH-D and CRC risk (OR = 0.7,
95% CI 0.56–0.87), suggesting the
association was mediated through
the vitamin D binding to the VDR.

IV

The study failed
to demonstrate
causal effect because of a lack
of RCT design.

CI—confidence interval; CRC—colorectal cancer; HR—hazard ratio; HRT—hormone replacement therapy; OR—odds ratio; RCT—randomized, controlled
trial; RR—risk ratio; VDR—vitamin D receptor
Note. Level of evidence II indicates evidence from at least one well-designed RCT; level IV indicates evidence from well-designed case-control and cohort
studies.

colorectal epithelium apoptosis (Diaz, Paraskeva, Thomas, Binderup, & Hague, 2000; Miller et al., 2005).
An effective dosage of vitamin D to raise 25-OH-D levels above
80 nmol/L (32 ng/ml) is critical in achieving cancer risk reduction. Previous investigators have demonstrated a dose-response
relationship between cancer risk and 25-OH-D levels. Quantitative pooled analyses from cohort studies reveal that correction
of vitamin D deficiency to an optimal level of 33 ng/ml or higher
(82.5 nmol/L) is associated with a 50% reduction in colorectal
cancer risk (Gorham et al., 2007), while a level of 52 ng/ml or
higher (130 nmol/L) is associated with a 50% beast cancer risk
reduction (Garland et al., 2007). In the study by Lappe et al.
(2007), vitamin D intake of 1,100 IU per day raised 25-OH-D
levels from a baseline of 71.8 nmol/L to 96 nmol/L. However,
in the WHI study, vitamin D intake of 400 IU per day was too
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low to raise 25-OH-D levels above 80 nmol/L to achieve any
meaningful cancer risk reduction. Given these mixed results, a
RCT in a large sample using an effective vitamin D dose to keep
25-OH-D level within the range of 32–100 ng/ml (measured
twice a year in both winter and summer) over 10 years is needed
to provide the strongest evidence of vitamin D’s long-term effects in cancer risk reduction.

Dose Response Between 25-OH-D Level
and Colorectal Cancer Risk
Eleven studies based on cohort and case-control research
designs examined the relationship between serum 25-OH-D
levels and colorectal cancer risk. Seven of the studies showed
various degrees of risk reduction for colorectal cancer and four
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for colorectal adenoma at higher serum 25-OH-D levels. The
major limitations of the studies were that they were unable to
demonstrate causal effects between vitamin D and colorectal
cancer risk and that the 25-OH-D levels were mostly one-time
measurements, which may not accurately represent vitamin
D status because 25-OH-D levels fluctuate with seasonal
changes.
Seven studies evaluated the effects of serum 25-OH-D levels
on colorectal cancer risk. A predictive model based on a cohort
study indicated that every 25 nmol/L increase in 25-OH-D levels
produces a 37% colorectal cancer reduction (RR = 0.63, 95% CI
0.48–0.83) (Giovannucci et al., 2006). Wu et al. (2007) conducted
a nested control study from the cohort of the Health Professional
Follow-Up Study (HPFS), pooled the data with the Nurse Health
Study (NHS) for analysis, and found a significant inverse relationship for colon cancer risk between the highest and the lowest
quintile of 25-OH-D levels in the HPFS cohort (fifth quintile = 39.4
ng/ml and first quintile = 18.4 ng/ml, OR = 0.46, 95% CI 0.24–0.89,
p = 0.005). The pooled analysis with the NHS showed significantly decreased risks for total colorectal and colon cancer comparing the highest to the lowest quintile of 25-OH-D levels (total
colorectal cancer OR = 0.66, 95% CI 0.42–1.05, p = 0.01; colon
cancer OR = 0.54, 95% CI 0.34–0.86, p = 0.002). The third study
of the NHS cohort alone (Feskanich et al., 2004) revealed that
25-OH-D levels were inversely associated with colorectal cancer
risk (fifth quintile versus first quintile OR = 0.53, 95% CI 0.27–1.04,
p = 0.02). For women older than 60 years of age, the OR for colorectal cancer risk from the highest quintile of 25-OH-D levels
was 0.35 (95% CI 0.14–0.87, p = 0.006), but no dose-response
relationship was found between colorectal cancer risk and level
of 1-25-OH-D (the hormonal form of vitamin D). Similarly, a casecontrol study by Sieg et al. (2006) supported that higher 25-OH-D
levels were associated with significantly lowered colorectal
cancer risk.
Otani, Iwasaki, Sasazuki, Inoue, and Tsugane (2007) conducted a population-based, nested-control study of 25-OH-D
levels and colorectal cancer risk in Japan and found the lowest
quartile of 25-OH-D level was associated with an elevated risk
of rectal cancer in men (lowest quartile of less than 23 ng/ml
versus highest quartile of more than 32.1 ng/ml, OR = 4.6, 95%
CI 1–20) and women (lowest quartile of less than 18.7 ng/ml
versus highest quartile of more than 27 ng/ml, OR = 2.7, 95% CI
0.94–7.6). However, Freedman, Looker, Chang, and Graubard
(2007) examined the effect of 25-OH-D levels on cancer mortality from the cohort of the Third National Health and Nutrition Examination Survey and found no relationship between
25-OH-D levels and total cancer mortality. However, 25-OH-D
levels of 80 nmol/L (32 ng/ml) or higher were associated with
a 72% reduction in colorectal cancer mortality (95% CI 32–89)
compared with 25-OH-D levels of less than 50 nmol/L (p =
0.02). Ng et al. (2008) analyzed the influence of prediagnosis
serum 25-OH-D levels on colorectal cancer–specific mortality
from the cohort of the HPFS and the NHS and reported that
25-OH-D levels significantly reduced the overall mortality (lowest quartile of less than 18.8 ng/ml versus highest quartile of
more than 29ng/ml, HR = 0.52, 95% CI 0.29–0.94, p for trend
= 0.02). A statistically nonsignificant trend existed toward
improved colorectal cancer-specific mortality (HR = 0.61, 95%
CI 0.31–1.19, p for trend = 0.23)

Patient Education Resources on Vitamin D Deficiency
Mayo Clinic: www.mayoclinic.com/health/vitamin-d/NS_patient-vitamind
Merck Manuals: www.merck.com/mmhe/sec12/ch154/ch154j.html
Vitamin D Council: www.vitamindcouncil.org
WebMD: www.webmd.com/food-recipes/features/are-you-getting-enough
-vitamin-d?page=2&print=true

Video Clips on Vitamin D Deficiency
Vitamin D and cancer prevention: www.youtube.com/watch?v=1Psya
YNX1dw&feature=channel
What’s a vitamin D deficiency? www.youtube.com/watch?v=emj
CzaHtSrg

Four other studies examined serum 25-OH-D levels and
colorectal adenoma risk. Jacobs et al. (2006) examined the
sample cohort originating from the Ursodeoxycholicacid Trial
for adenoma prevention and found a moderate, non-significant
inverse association between 25-OH-D levels and adenoma recurrence. Interestingly, Miller et al. (2005) revealed that higher
25-OH-D levels were associated with higher rectal epithelium
apoptosis for patients with or without adenomas. Peters et
al. (2004) conducted a nested case-control study within the
Prostate, Lung, Colorectal and Ovarian Cancer Screening trial.
Comparing the highest quintile (greater than 36.6 ng/ml) with
the lowest quintile (19.2 ng/ml or lower) of 25-OH-D levels, the
risk for advanced adenoma was decreased by 73% in women
(OR = 0.27, 95% CI 0.11–0.69, p = 0.0002), but the risk was not
decreased in men (OR = 1.1, 95% CI 0.6–2.05, p = 0.85). Again,
serum 1-25-OH-D was not associated with advanced adenoma
risk. Grau et al. (2003) assessed the cohort from the Calcium
Polyp Prevention Trial and found a joint effect of 25-OH-D
levels and calcium on adenoma recurrence. Only subjects
with a 25-OH-D level above the median of 29.1 ng/ml and
taking 1,500 mg of calcium daily demonstrated a statistically
significant reduction for adenoma recurrence (RR = 0.71, 95%
CI 0.57–0.89, p = 0.01).
In summary, serum 25-OH-D levels, which represent vitamin
D status, have consistently revealed an inverse relationship with
colorectal cancer and colorectal adenoma risks. The lower the
level, the higher the risk. The levels of 25-OH-D in Grau et al.
(2003), Jacobs et al. (2006), Miller et al. (2005), and Peters et al.
(2004) demonstrated a significant colorectal cancer or adenoma
risk reduction in the range of 27–39.4 ng/ml, with a median of
33 ng/ml. Such a level is well within the normal range of 32–100
ng/ml for 25-OH-D levels.

Vitamin D Intake and Colorectal Cancer Risk
Ten studies measured the effect of vitamin D intake from diet
and supplementation on colorectal cancer risk using cohort or
case-control designs. Although level IV evidence is assigned
for these studies, the measurement of vitamin D intake may
not truly reflect vitamin D status because many factors affect
such status, including age, obesity, physical activity, skin color,
sunshine exposure, and smoking history (Holick, 2007). Moreover, the amount of vitamin D intake cannot be determined
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accurately because food survey questionnaires were used to
estimate the amount of vitamin D intake for individuals.
Seven of the 10 studies revealed favorable findings regarding
higher vitamin D intake and colorectal tumor risk reduction. For
example, one population-based case-control study in Scotland
found that vitamin D intake from diet and supplementation
significantly reduced colorectal cancer risk (Theodoratou et al.,
2008). Another case-control study conducted in Japan reported
that the combination of high vitamin D, calcium intake, and high
sun exposures resulted in the greatest colorectal cancer risk
reduction compared to each factor alone (Mizoue et al., 2008).
Similarly, two additional studies demonstrated that high levels of
vitamin D intake, increased consumption of low fat dairy products, or high levels of sunshine exposure decreased colorectal
cancer risk (McCullough et al., 2003; Slattery et al., 2004).
Interestingly, Park et al. (2007) examined vitamin D intake
and colorectal cancer risk from a multiethnic cohort sample in
California and Hawaii and found an inverse association between
total vitamin D intake and colorectal cancer risk in men (RR =
0.72, 95% CI 0.51–1, p = 0.03) but not in women (RR = 0.89, 95%
CI 0.63–1.27, p = 0.8). However, women who had high vitamin D
intake from foods showed a significantly lowered risk (RR = 0.78,
95% CI 0.93–0.96), which was even more evident in women who
did not take supplements (RR = 0.69, 95% CI 0.52–0.93, p = 0.03).
Two studies assessed the effect of vitamin D intake on colorectal
adenomas. One examined the NHS cohort and found that total
vitamin D intake was weakly associated with reduced risk of combined distal colorectal adenomas (RR = 0.79, 95% CI 0.63–0.99,
p = 0.07), and more strongly associated with distal colon adenoma
risk reduction (RR = 0.67, 95% CI 0.52–0.87, p = 0.004) (Oh, Willett, Wu, Fuchs, & Giovannucci, 2007). Another study investigated
vitamin D intake on polyp recurrence from the cohort of the Polyps Prevention Trial and determined that total vitamin D intake
was inversely (although weakly) associated with adenoma recurrence, comparing the fifth to the first intake quintiles (OR = 0.84;
95% CI 0.62–1.13, p = 0.03; for vitamin D supplementation, OR =
0.82, 95% CI 0.68–0.99) (Hartman et al., 2005). Overall, vitamin D
appeared to be more effective in preventing multiple recurrences
of polyps (OR = 0.73, 95% CI 0.53–0.99) (Hartman et al.).
Conversely, three studies did not find an inverse relationship
between vitamin D intake and colorectal cancer risk. The first
study examined the relationship between vitamin D intake and
the risk of colorectal adenoma and colorectal cancer among a
large group of French women (N = 74,524) with no association
found between colorectal tumor and vitamin D intake after
almost seven years of follow-up (Kesse, Boutron-Ruault, Norat,
Riboli, & Clavel-Chapelon, 2005). However, this sample had
a low consumption of vitamin D, with the 90th percentile of
4.34 mcg per day (less than 400 IU per day). A second study
conducted in the United States reported similar findings when
analyzing vitamin D intake in the large WHI female cohort (N =
36,976) (Lin et al., 2005). The median vitamin D intake of 271
IU per day also was low in this sample (Lin et al., 2005). Likewise, Martinez, Marshall, Sampliner, Wilkinson, and Alberts
(2002) assessed the effect of vitamin D intake from dietary and
supplemental sources on colorectal adenoma recurrence among
1,304 men and women who had polyps removed within three
months of study entry. They were unable to detect any significant impact of vitamin D intake on polyp recurrence after an
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average follow-up time of three years; however, the vitamin D
dose for cutoff in this analysis also was low, about 400 IU per
day. Therefore, low doses of vitamin D intake likely contributed
to the non-significant results in colorectal cancer risk reduction
in all three studies.
In summary, the studies of vitamin D intake and colorectal
tumor risk reveal inconsistent results. Vitamin D intake may
only represent a portion of the overall vitamin D resource
availability and is, therefore, unable to reflect true vitamin D
status. In addition, vitamin D intake was estimated from food
questionnaires, which were subject to measurement errors
and recall biases. Moreover, different studies adopted different
food questionnaires. Despite these limitations, higher vitamin
D intake generally decreased colorectal tumor risk.

Safety, Cost, and Benefits
Vitamin D intoxication (hypercalcemia and hyperphosphatemia) occurs when 25-OH-D levels reach 150 ng/ml (375
nmol/L) (Holick, 2007). However, as described earlier, 1,100 IU
per day of vitamin D revealed no difference in toxicity profile
compared with placebo (Lappe et al., 2007). In Hathcock, Shao,
Vieth, and Heaney (2007), subjects taking 10,000 IU per day
of vitamin D for up to five months did not demonstrate toxic
effects. In light of these findings, many experts are urging the
Food and Nutrition Board of the Institute of Medicine to update
the original vitamin D recommendation from 1997 because it
no longer is supported by the evidence. The U.S. Food and Drug
Administration (FDA) recommendations for vitamin D are 200
IU per day for ages 19–50, 400 IU per day for age 51–70, and 600
IU per day for ages 71 and older.
Studies suggest that vitamin D intake should be around 1,000 IU
per day to provide benefits for bone health and cancer risk reduction (Lappe et al., 2007; Vieth et al., 2007). Considering that more
than 50% of Americans and about 80% of cancer survivors use
dietary supplements without medical advice (Miller et al., 2008;
Velicer & Ulrich, 2008), an evidence-based vitamin D recommendation will help guide the general public regarding safety and
quality-of-life outcomes. Grant, Garland, and Gorham (2007) estimated that 1,000 IU per day of vitamin D would result in a 7%–9%
absolute cancer reduction in the United States and a 14%–20%
cancer reduction in Western Europe. In short, the overall health
benefits of vitamin D greatly outweigh the potential risks (Grant
& Garland, 2008). In fact, to date, no health risk associated with
daily vitamin D intake of 1,000–2,000 IU has been reported.
Regarding the financial savings associated with increased vitamin D intake, the cost-to-benefit ratio can be calculated based on
Lappe et al. (2007), which noted that treating 20 people prevents
one cancer case over four years. The per-person cost of 1,000 IU
per day of vitamin D is about $20 per year, or $80 for four years per
person, which translates into $1,600 for 20 people over four years.
In 2008, the overall cost for one cancer case was about $152,520,
calculated from the estimated 1,437,180 cancer cases with a cost of
$219.2 billion based on ACS (2008). Dividing the cost for one cancer case in 2008 ($152,520) by four years equals $38,130, meaning
that for every $1,600 spent on vitamin D, a potential cost-saving of
$38,130 in cancer treatment exists. This yields an excellent costbenefit ratio of 1:24 just from cancer alone.
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Suggested Recommendations
Healthcare providers play important roles in disease prevention, health promotion, and education. Because vitamin D
deficiency is a widespread public health issue linked to cancer
and other health risks, healthcare providers should not ignore
this easily correctable condition. The FDA recommendations
for vitamin D were set by the Institute of Medicine in 1997, but
results from the WHI suggest that these recommendations are

ineffective in preventing vitamin D deficiency as well as decreasing the risk for osteoporotic fractures and colorectal cancer
development (Jackson et al., 2006; Wactawski-Wende et al.,
2006). Higher vitamin D dosages of 700–1,100 IU per day used in
previously cited RCTs resulted in 25-OH-D levels in the 80–100
nmol/L range with subsequent reductions in fracture and cancer
risks (Bischoff-Ferrari et al., 2005; Lappe et al., 2007). Previous
studies also have clearly revealed that vitamin D status (25-OH-D
level) and vitamin D intake are inversely associated with cancer

Table 2. Treatment Recommendations for Vitamin D Deficiency
Recommendation

Rationale

Encourage patients to take
1,000 IU per day of vitamin D
plus 1,200–1,500 mg of daily
calcium if 25-OH-D levels are
not available.

These supplemental amounts have been shown to reduce overall cancer risks, including risks for colorectal cancer
(Gorham et al., 2007; Lappe et al., 2007) and fracture risks (Bischoff-Ferrari et al., 2005).

Screen 25-OH-D levels twice a
year (near the end of summer
and near the end of winter)
for high-risk individuals.

Subclinical vitamin D deficiency (less than 32 ng/ml) is common in the general population, and the prevalence among
patients with cancer and individuals with osteoporosis or osteopenia is alarmingly high (Everett, 2008; Hershman et
al., 2006; Holick, 2007; Li et al., 2007; Lips et al., 2006; Maddipatla et al., 2007). Because 25-OH-D levels fluctuate with
seasons because of sun exposure, measuring these levels twice a year provides more accurate assessment of vitamin D
status (Freedman et al., 2007). Parathyroid hormone (PTH) levels also should be checked for individuals with osteopenia
or osteoporosis and patients with metastatic bone disease. Vitamin D deficiency should be corrected prior to initiating
bisphosphonate therapy to prevent hypocalcemia (Wang-Gillan et al., 2006; Yazbeck et al., 2007). Individuals at highest risk of vitamin D deficiency include those with the following conditions or circumstances: cancer; osteoporosis and
osteopenia; chronic kidney disease; liver disease; fibromyalgia; migraine headaches; gastrointestinal malabsorption,
which often occurs after gastrectomy or gastric bypass procedures; Crohn disease; celiac spruce disease; people living in
northern latitudes; older adults; young children; people who are homebound; people who have darker skin color; people
who are obese or inactive; or people who are taking certain medications such as anticonvulsants, glucocorticoids, HIV/
AIDS treatments, and antirejection drugs after organ transplantation (Holick, 2007).

Correct vitamin D deficiency
through vitamin D repletion.

Raising 25-OH-D levels within a range of 32–100 ng/ml results in numerous positive health outcomes, including
stronger bones, colorectal cancer risk reduction, and increased muscle strength to reduce falls, which is particularly
important for older adults (Bischoff-Ferrari et al., 2006). For every 40 IU (1 mcg) of vitamin D3, serum 25-OH-D levels
increase by about 1 nmol/L (0.4 ng/ml) (Heaney et al., 2003). Very low levels of 25-OH-D may require prescription
strength vitamin D (50,000 IU in D2 form in the United States). For 25-OH-D levels less than 20–32 ng/ml, consider
50,000 IU of vitamin D2 weekly for four to five weeks; for 25-OH-D levels less than 15–20 ng/ml, consider 50,000 IU
of vitamin D2 weekly for eight weeks (Lyman, 2005); and for 25-OH-D levels less than 15 ng/ml, consider 50,000 IU of
vitamin D2 twice a week for five weeks (Adams et al., 1999). Recheck 25-OH-D levels one to two weeks after repletion, with repetition of repletion based on the level-dose recommendations if 25-OH-D levels do not increase above
32 ng/ml.a

Maintain vitamin D at the sufficient state with 25-OH-D levels in the range of 32–100 ng/
ml; however, levels of 50–100
ng/ml are optimal for most
patient populations.a

Without vitamin D maintenance after repletion, 25-OH-D levels will drop in two to four months because vitamin D
has a half-life of one to two months (Vieth, 1999). The optimal 25-OH-D level of 50–100 ng/ml is preferred for colon
cancer and breast cancer risk reduction (Garland et al., 2007; Gorham et al., 2007). Alternatively, Cannell and Hollis
(2008) proposed that, for patients with serious illnesses associated with vitamin D deficiency such as cancer, heart
disease, multiple sclerosis, diabetes, autism, and a host of other illnesses, doses should be sufficient to maintain
year-round 25-OH-D levels from 55–70 ng/ml. Recommend a maintenance dose of 1,000 IU of vitamin D3 daily (Lyman, 2005). Because poor adherence to daily dosing is common, an alternative is to prescribe 50,000 IU of vitamin
D2 once or twice per month (e.g., once a month in summer and twice per month in winter). Many patients prefer this
approach with fewer pills. For those reluctant to take pills, recommend vitamin D rich foods, such as oily fish (e.g.,
salmon, tuna, canned sardines, mackerel), fortified foods, cod liver oil, and Shiitake mushrooms (Holick, 2007).

Advise concurrent calcium
intake of 1,200 mg daily for
men and premenopausal
women, and 1,500 mg daily
for postmenopausal women
and individuals with osteoporosis or osteopenia.

Calcium and vitamin D work jointly to promote strong bones and reduce cancer risk, as evidenced by the fact that
most randomized, controlled trials have incorporated vitamin D and calcium as the intervention for cancer and fracture risk reduction (Bischoff-Ferrari et al., 2005; Lappe et al., 2007).

For individuals with chronic granulomatous disorders, such as sarcoidosis and some lymphomas, 25-OH-D levels should be kept at lower range of
20–30 ng/ml because of higher sensitivity to circulating 25-OH-D (Holick, 2007), primarily from the unregulated production of calcitriol (1-25-OH-D)
from activated macrophage in sarcoidosis associated with a risk of hypercalcemia (Conron et al., 2000; Sharma, 2000). Individuals with primary hyperparathyroidism and chronic kidney disease associated vitamin D deficiency should be referred to a specialist in lieu of clinical management.
a
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risks, particularly for colorectal cancer (Garland et al., 2006).
Therefore, optimizing vitamin D intake provides “win-win”
benefits of correcting vitamin D deficiency, promoting bone
health, and reducing colorectal cancer risks. Based on currently
available evidence, Table 2 outlines treatment recommendations
for vitamin D deficiency.

Implications and Conclusion
Although government healthcare agencies have not adopted
any vitamin D recommendations for cancer risk reduction,
current evidence is substantial and compelling and supports
the role of vitamin D in reducing colorectal cancer risk. Nationally and internationally, many experts are urging healthcare
agencies and international food and nutritional boards to recommend an effective allowance for vitamin D intake (Veith et
al., 2007). Ideally, more definitive evidence of vitamin D on
any cancer risk reduction should be obtained through large,
population-based, longitudinal RCTs with adequate doses of
vitamin D as interventions. However, such trials are expensive,
and sales of vitamin D, a rather low-cost supplement, cannot
generate enough profits to offset the trial cost. However, the
Vitamin D/Calcium Polyp Prevention Study (2004–2017), a
double-blinded, four-arm RCT with 2,200 subjects, currently
is underway to evaluate the effects of placebo, calcium (1,200
mg per day), vitamin D (1,000 IU per day), and calcium plus
vitamin D (1,200 mg plus 1,000 IU per day) on colorectal neoplasia risk reduction, but the result will not be available until
after the study’s completion. (For more information on the
trial, visit http://clinicaltrials.gov/ct2/show/NCT00153816.)
In the meantime, vitamin D debates will continue regarding
optimal vitamin D intakes, optimal vitamin D status, emerging roles of vitamin D, and so forth, adding the complexity of
future vitamin D researches (Beres, 2008).
Considering that more than 50% of Americans and 80% of
cancer survivors are taking dietary supplements without clinical
advice (Miller et al., 2008; Velicer & Ulrich, 2008), and acknowledging the overall safety profile of vitamin D and its wide range
of health benefits, recommending that patients take 1,000 IU of
vitamin D daily is reasonable and practical and clinicians should
make every effort to promote and maintain optimal vitamin D
status in their patients. Above all, given that patient care is a multifaceted process, clinicians must consider the current research
evidence, their patients’ condition and preferences, and their
own experiences and judicious clinical judgment in addressing
the need for vitamin D supplementation.
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Journal Club Discussion Questions
This article has been identified as appropriate for a journal club. When you read this article, think about how you would change
your current practice regarding screening and managing vitamin D deficiency in your patients. See the Evidence-Based Practice
column in the February 2009 Clinical Journal of Oncology Nursing (Vol. 13, No. 1, pp. 109–112) on how to implement and participate in journal clubs. Photocopying of this article for discussion purposes is permitted.
1.
2.
3.
4.
5.

What is the clinical practice question the authors are trying to answer?
Is the purpose of the article described clearly?
Is the literature review comprehensive and are major concepts identified and defined?
Are the clinical recommendations supported by evidence? What are they?
Do you currently screen patients for vitamin D deficiency? How do the clinical recommendations compare to your current
practice?
6. What practice change recommendations will you make based on the evidence presented in this article? Who should get
screened for vitamin D deficiency? When, where, and how often should they be screened? How should someone be managed
if deficient?
7. What patient education materials are available on this topic?
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